 WOBURN, Mass., Aug. 01, 2022 GLOBE NEWSWIRE -- Replimune Group, Inc. NASDAQ: REPL, a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: 